Terminated PHASE2 INTERVENTIONAL 3-arm NCT05005507

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection (PENGUIN-2)

A Phase 2, Open-label, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Patients With Chronic Hepatitis B Virus Infection

Sponsor: Janssen Research & Development, LLC

Conditions Hepatitis B, Chronic

Interventions ETV JNJ-73763989 PegIFN-alpha-2a TAF Tenofovir disoproxil

Updated 11 times since 2021 Last updated: Feb 8, 2024 Started: Nov 3, 2021 Primary completion: Dec 29, 2021 Completion: Dec 29, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

A strategic decision was made to not further execute the study. This decision was not based on a safety concern.

Other terminated trials from Janssen Research & Development, LLC

More terminations from Janssen Research & Development, LLC

Other Hepatitis B, Chronic trials with similar outcome

Browse all Hepatitis B, Chronic trials

A PHASE2 clinical study on Hepatitis B, Chronic, this trial is terminated or withdrawn. The trial is conducted by Janssen Research & Development, LLC and has accumulated 11 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

11 versions recorded

Dec 2025 — Present [monthly]

Terminated PHASE2
Sep 2025 — Dec 2025 [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Apr 2024 — Jul 2024 [monthly]

Terminated PHASE2

▶ Show 6 earlier versions

Feb 2023 — Apr 2024 [monthly]

Terminated PHASE2
Mar 2022 — Feb 2023 [monthly]

Terminated PHASE2

Status: Recruiting → Terminated
Jan 2022 — Mar 2022 [monthly]

Recruiting PHASE2
Dec 2021 — Jan 2022 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Oct 2021 — Dec 2021 [monthly]

Not Yet Recruiting PHASE2
Sep 2021 — Oct 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Research & Development, LLC

Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Gdansk, Poland , Hillsborough, United States , Madrid, Spain , Mysłowice, Poland , Santander, Spain , Tainan, Taiwan , Takamatsu, Japan , Vancouver, Canada , Vigo, Spain and 1 more location